The University of Chicago Header Logo

Connection

Richard Larson to Drug Substitution

Back to Details
This is a "connection" page, showing publications Richard Larson has written about Drug Substitution.
Richard Larson
Connection Strength
0.026
Drug Substitution
  1. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.